Optimizing the Use of Checkpoint Inhibitors in NSCLC
Meeting Series
Meeting Series

Optimizing the Use of Checkpoint Inhibitors in NSCLC

Continuing to Rally the Troops

Not a member of My prIME? Join now for instant access.

This live meeting series is designed specifically for clinicians who treat and manage veterans with lung cancer. The content will provide an update on the latest information on immunotherapy, patient identification, adverse event management, and treatment selection. The update will be followed by case presentation and discussion.

CME

CME

1.0 AMA PRA Category 1 Credit

Albuquerque, New Mexico

Tuesday, November 27, 2018

Turner Board Conference Room
Raymond G. Murphy VA Medical Center
1501 San Pedro Drive SE
Albuquerque, New Mexico
87108

Corey Carter, MD
John P. Murtha Cancer Center
Walter Reed National Military Medical Center
National Cancer Institute/National Institutes of Health
Bethesda, Maryland, United States

Long Beach, California

Friday, November 30, 2018

Auditorium
College Medical Center
2776 Pacific Avenue
Long Beach, California
90806

Karen Reckamp, MD
City of Hope
Duarte, California, United States

Murfreesboro, Tennessee

Friday, December 7, 2018

4th Floor Conference Room
Alvin C. York Campus
VA Tennessee Valley Healthcare System
3400 Lebanon Pike
Murfreesboro, Tennessee
37129

Leora Horn, MD
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States

5 min Welcome and introduction
5 min Oncology Guru: What do you know about checkpoint inhibition in lung cancer?
5 min Checkpoint inhibitors: Mechanisms of action
18 min Using checkpoint inhibitors to treat lung cancer
7 min Immune-related adverse events: Identification and management
8 min Incorporating checkpoint inhibitors into treatment of non-small cell lung cancer (NSCLC): An interactive exercise
5 min Assessing what you have learned from this activity: Have you increased your “guru” status?
7 min prIME Points™, questions & answers, conclusion

Chairs

  • Corey Carter, MDJohn P. Murtha Cancer Center
    Walter Reed National Military Medical Center
    National Cancer Institute/National Institutes of Health
    Bethesda, Maryland, United States
  • Leora Horn, MDVanderbilt-Ingram Cancer Center
    Nashville, Tennessee, United States

Presenting Faculty

  • Hossein Borghaei, DOFox Chase Cancer Center
    Philadelphia, Pennsylvania, United States
  • Christina Brzezniak, MDWalter Reed National Military Medical Center
    Bethesda, Maryland, United States
  • Millie Das, MDVA Palo Alto Health Care System
    Stanford Cancer Center
    Palo Alto, California, United States
  • Jonathan Dowell, MDUT Southwestern Medical Center
    VA North Texas Health Care System-Dallas
    Dallas, Texas, United States
  • Apar K. Ganti, MDVA Nebraska/Western Iowa Health Care System
    University of Nebraska Medical Center
    Omaha, Nebraska, United States
  • Karen Reckamp, MDCity of Hope
    Duarte, California, United States

This educational activity is designed to meet the needs of medical, surgical, and radiation oncologists, as well as advanced practitioners and mid-level providers, who treat/manage patients with lung cancer in the VA system or in the VA choice programs.

After successful completion of this educational activity, participants should be able to:

  • Describe the mechanisms of action of checkpoint inhibitors used in the treatment of lung cancer
  • Design optimal strategies for the treatment of non-small cell lung cancer (NSCLC) that incorporate the use of checkpoint inhibitors
  • Implement management strategies to address immune-related adverse events (irAEs) related to the use of checkpoint inhibitors

This educational activity is supported by a grant from Merck and Co, Inc.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Americans With Disabilities Act

Event staff will be glad to assist you with any special needs (physical, dietary, etc). Please contact Daphaney Willis prior to the live event at 678.686.7759.

There is no fee for this activity.

Disclosures

Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.